製品番号: HY-146548

Anticancer agent 43

カスタマーレビュー

Based on 1 Customer Validation

Anticancer Agent 43 is a potent anticancer agent. Anticancer Agent 43 induces apoptosis by caspase 3, PARP1, and Bax dependent mechanisms. Anticancer Agent 43 induces DNA damage.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.58%
CAS 番号: 2470015-35-9
分子式: C₁₄H₉FN₂O₃S₂
分子量:336.36

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Anticancer agent 43 構造式

CAS 番号: 2470015-35-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Anticancer Agent 43 is a potent anticancer agent. Anticancer Agent 43 induces apoptosis by caspase 3, PARP1, and Bax dependent mechanisms. Anticancer Agent 43 induces DNA damage^[1].

IC₅₀ & Target^[1]

Caspase 3

PARP1

Bax

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

PARP アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	9.7 μM Compound: 3a	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
BALB/3T3	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay	[PMID: 34634616]
BALB/3T3	GI₅₀	25 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	40.8 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	48.3 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
BALB/3T3	GI₅₀	51.5 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay	[PMID: 34634616]
BALB/3T3	GI₅₀	54.3 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	62.8 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay	[PMID: 34634616]
BALB/3T3	GI₅₀	89.7 μM Compound: 3a	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay	[PMID: 34634616]
HaCaT	GI₅₀	98.3 μM Compound: 3a	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HCT-116	GI₅₀	0.8 μM Compound: 3a	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HeLa	GI₅₀	49.3 μM Compound: 3a	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	>100 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
HepG2	GI₅₀	0.04 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by LDH assay	[PMID: 34634616]
HepG2	GI₅₀	0.06 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by LDH assay	[PMID: 34634616]
HepG2	GI₅₀	0.31 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by LDH assay	[PMID: 34634616]
HepG2	GI₅₀	12.1 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	16.3 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	24.5 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by neutral red uptake assay	[PMID: 34634616]
HepG2	GI₅₀	35.6 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
HepG2	GI₅₀	40.1 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by neutral red uptake assay	[PMID: 34634616]
HepG2	GI₅₀	44.7 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34634616]
HepG2	GI₅₀	63.9 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by coomassie brilliant blue staining based total cellular protein assay	[PMID: 34634616]
HepG2	GI₅₀	7.5 μM Compound: 3a	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by neutral red uptake assay	[PMID: 34634616]
MCF7	GI₅₀	0.7 μM Compound: 3a	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
THP-1	GI₅₀	62.4 μM Compound: 3a	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
WM793	GI₅₀	80.4 μM Compound: 3a	Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]

体外実験

Anticancer agent 43 (compound 3a) shows selectivity toward human tumor cells (SI₅₀=28.94)^[1].
Anticancer agent 43 (45 µM, 24 h) induces apoptosis via caspase 3, PARP1 and Bax dependent pathways in HepG2 cells^[1].
Anticancer agent 43 (45 µM, 24 h) shows no effect on the transition of G1/S phases in HepG2 cells^[1].
Anticancer agent 43 (0.7, 45, 55 µM) induces DNA damage in HCT116 cells (Tail DNA=16.1%, OTM=3.7), MCF-7 cells, HepG2 cells (Tail DNA=26.2%, OTM=13.2), Balb/c 3T3 cells (Tail DNA = 8.4%, OTM = 3.5)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

HepG2, MCF-7, HCT116, HeLa, A549, WM793, THP-1, HaCaT, Balb/c3T3 cells
Concentration:

0, 1, 10, 100 µM
Incubation Time:

72 h
Result:

Showed cytotoxic action with GI₅₀s of 12.1, 0.7, 0.8, 49.3, 9.7 µM for for HepG2, MCF-7, HCT116, HeLa, A549 cells, low toxicity towards WM793, THP-1, HaCaT, Balb/c 3T3 cells with GI₅₀s of 80.4, 62.4,98.3,40.8 µM , respectively.

Apoptosis Analysis^[1]

Cell Line:

HepG2 cells
Concentration:

45 µM
Incubation Time:

24 h
Result:

Induced apoptosis in HepG2 cells via caspase 3, PARP1 and Bax dependent pathways.

Western Blot Analysis^[1]

Cell Line:

HCT116, MCF-7 cells
Concentration:

0.7 µM
Incubation Time:

24 h
Result:

Decreased the expression of Cdk2 protein in HCT116 and MCF-7 cells.

Cell Cycle Analysis^[1]

Cell Line:

HepG2 cells
Concentration:

45 µM
Incubation Time:

24 h
Result:

Showed no effect on the transition of G1/S phases in HepG2 cells.

化学情報

CAS 番号 2470015-35-9
性状 Solid
分子量 336.36
分子式 C₁₄H₉FN₂O₃S₂
Color Light yellow to yellow
SMILES

COC(C1=C(C2=C(N1)C=CC(F)=C2)/C=C3SC(NC\3=O)=S)=O
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (371.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9730 mL

14.8650 mL

29.7301 mL

5 mM

0.5946 mL

2.9730 mL

5.9460 mL

10 mM

0.2973 mL

1.4865 mL

2.9730 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kryshchyshyn-Dylevych A, et al. Synthesis of novel indole-thiazolidinone hybrid structures as promising scaffold with anticancer potential. Bioorg Med Chem. 2021; 50:116453. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9730 mL	14.8650 mL	29.7301 mL	74.3251 mL
	5 mM	0.5946 mL	2.9730 mL	5.9460 mL	14.8650 mL
	10 mM	0.2973 mL	1.4865 mL	2.9730 mL	7.4325 mL
	15 mM	0.1982 mL	0.9910 mL	1.9820 mL	4.9550 mL
	20 mM	0.1487 mL	0.7433 mL	1.4865 mL	3.7163 mL
	25 mM	0.1189 mL	0.5946 mL	1.1892 mL	2.9730 mL
	30 mM	0.0991 mL	0.4955 mL	0.9910 mL	2.4775 mL
	40 mM	0.0743 mL	0.3716 mL	0.7433 mL	1.8581 mL
	50 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4865 mL
	60 mM	0.0496 mL	0.2478 mL	0.4955 mL	1.2388 mL
	80 mM	0.0372 mL	0.1858 mL	0.3716 mL	0.9291 mL
	100 mM	0.0297 mL	0.1487 mL	0.2973 mL	0.7433 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Anticancer agent 43

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Pyroptosis Compound Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Heterocyclic Compound Library

Cell Death Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Bcl-2 Family アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

PARP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Anticancer agent 43

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Pyroptosis Compound Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Heterocyclic Compound Library

Cell Death Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Bcl-2 Family アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

PARP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Anticancer agent 43 関連分類

HY-146548 関連分類